Loading...
NASDAQ: ILMN
Illumina, Inc.
Healthcare · Medical - Diagnostics & Research
Market Cap
$18.87B
52w High
$155.53
52w Low
$68.70
P/E
22.21
Volume
244.46K
Outstanding Shares
152.90M
Company profile
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis.
CEOJacob Thaysen
SectorHealthcare
IndustryMedical - Diagnostics & Research
Employees8,970
IPO dateJul 28, 2000
Valuation
Forward P/E—
EV/EBITDA14.90
Enterprise value$21.71B
Stock splits
Sep 23, 20082:1
Profitability & growth
Revenue growth4.98%
Gross margin66.49%▲1.61%vs FY2024
Operating margin19.92%▲204.56%vs FY2024
ROE31.22%▲160.57%vs FY2024
Analyst consensus
RatingBuy
Target price$147.13▲19.24%
25
Buy
19
Hold
6
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 14, 2026
View
EPS
Actual vs estimate by quarter
Q1FY25
ActualEst.
$0.97
$0.94
Q3FY25
ActualEst.
$1.34
$1.17
Q4FY25
ActualEst.
$1.35
$1.26
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q1FY25
ActualEst.
$1.04B
$1.03B
Q3FY25
ActualEst.
$1.08B
$1.07B
Q4FY25
ActualEst.
$1.16B
$1.07B
Q1FY26
Next Est.
—